Ahead of the upcoming COVAX AMC summit hosted by Germany on the 8th of April 2022, COVAX Civil Society and Community Representatives have issued a statement highlighting the urgent need for donors, governments, multilaterals, international financing institutions and the private sector to step up with support to ensure it succeeds. ACT-A needs US$48 billion is needed to
Statement on Global COVID-19 Summit from ACT-A Civil Society Representatives Following the Global COVID-19 Summit: Ending the Pandemic and Building Back Better on 22 September, the civil society representatives to ACT-A published a statement, recognising that whilst the the Summit aimed to catalyse and welcome momentum to progress the pandemic response, its targets fall far
The Platform for Civil Society and Community Representatives to ACT-A and the Gavi CSO Steering Committee are currently inviting applications for representatives to the COVAX Manufacturing Taskforce. The Civil Society & Communities Representatives to the COVAX Manufacturing Taskforce will advocate the viewpoints and needs of NGOs and Communities within the taskforce, working closely with the
COVAX Civil Society Representatives – Statement on the launch of the COVAX Investment Opportunity (April 2021)
As the COVAX investment opportunity is launched on Thursday 15 April, the civil society representatives to COVAX have published a statement on the need for a fully funded COVAX to ensure fair and equitable distribution to lifesaving COVID-19 vaccines globally. A copy of the statement can be found here.
Nomination Process: Civil Society Representatives to COVAX AMC Engagement Group and Shareholders Council
The Platform for Civil Society and Community Representatives to ACT-A and the Gavi CSO Steering Committee are currently inviting applications for four representatives, two civil society and community representatives to the AMC Engagement Group and two civil society and community representatives to the Shareholders Council. The two representatives to the AMC Engagement Group will be
The ACT-Accelerator (ACT-A) is designed to accelerate the development, production and equitable global access to safe, quality, effective, and affordable COVID-19 diagnostics, therapeutics and vaccines. Developing a vaccine against COVID-19 is one of the most pressing and complex challenge of our time. The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the